Evidence map›Paper›PMID 39399114›Full record

ArticleFrontiers in medicine2024

Development of prognostic models for advanced multiple hepatocellular carcinoma based on Cox regression, deep learning and machine learning algorithms.

Jie Shen, Yu Zhou, Junpeng Pei, Dashuai Yang, Kailiang Zhao, Youming Ding

Abstract read
In one paragraph

Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jie Shen *Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yu Zhou *Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Junpeng PeiDepartment of Hepatobiliary Surgery, 521 Hospital of Norinco Group, Xi'an, China.
Dashuai YangDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Kailiang ZhaoDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Youming DingDepartment of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Most patients with multiple hepatocellular carcinoma (MHCC) are at advanced stage once diagnosed, so that clinical treatment and decision-making are quite tricky. The AJCC-TNM system cannot accurately determine prognosis, our study aimed to identify prognostic factors for MHCC and to develop a prognostic model to quantify the risk and survival probability of patients. Methods: Eligible patients with HCC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database, and then prognostic models were built using Cox regression, machine learning (ML), and deep learning (DL) algorithms. The model's performance was evaluated using C-index, receiver operating characteristic curve, Brier score and decision curve analysis, respectively, and the best model was interpreted using SHapley additive explanations (SHAP) interpretability technique. Results: A total of eight variables were included in the follow-up study, our analysis identified that the gradient boosted machine (GBM) model was the best prognostic model for advanced MHCC. In particular, the GBM model in the training cohort had a C-index of 0.73, a Brier score of 0.124, with area under the curve (AUC) values above 0.78 at the first, third, and fifth year. Importantly, the model also performed well in test cohort. The Kaplan-Meier (K-M) survival analysis demonstrated that the newly developed risk stratification system could well differentiate the prognosis of patients. Conclusion: Of the ML models, GBM model could predict the prognosis of advanced MHCC patients most accurately.

Indexed as

advanced multiple hepatocellular carcinomadeep learninggradient boosted machinemachine learningprognosis

Identifiers

PMID39399114
PMCPMC11466773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.